结直肠癌治疗中的抗血管生成
Zhenni Yang1,2, Xuqian Zhang1,3, Xiaozhe Bai2
1Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianjin, China.
Cancer science
|January 17, 2024
概括
结肠直肠癌 (CRC) 是一个日益严重的全球健康问题. 本综述探讨了血管新生,其在CRC中的作用,以及治疗策略中的药物耐药性等挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 结肠直肠癌 (CRC) 发病率在全球和中国每年都在上升,在恶性瘤中排名第三.
- 血管新生,新血管的形成,通过提供营养物质和去除废物,对瘤生长至关重要.
- 血管内皮生长因子 (VEGF) 是血管新生过程中的关键调解者.
研究的目的:
- 审查结直肠癌中的血管生成的多方面的方面.
- 讨论涉及CRC血管生成的分子机制,信号通路和瘤微环境.
- 检查目前的治疗策略和药物耐药性 (DR) 的挑战,用于针对CRC的血管生成向疗法.
主要方法:
- 关于结肠直肠癌血管生成的科学文章的文献综述.
- 关于分子媒介,信号通路和瘤微环境的信息合成.
- 分析治疗方法和药物耐药性的机制.
主要成果:
- 血管新生是CRC的一个关键标志,对于瘤进展和转移至关重要.
- VEGF信号传递是血管生成的主要驱动因素,使其成为抗癌药物的目标.
- 对抗血管生成疗法的耐药性 (DR) 是一个重大的临床挑战,需要进一步研究.
结论:
- 了解CRC中的血管生成对于开发有效的治疗策略至关重要.
- 针对血管生成途径提供治疗潜力,但必须解决药物耐药性的机制.
- 对分子标,微环境调制和克服DR的进一步研究对于改善CRC患者的治疗结果至关重要.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Mechanism of Angiogenesis
5.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K


